KAZIA THERAPEUTICS LTD

Kazia Therapeutics Limited announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Mr. Levine brings over two decades of experience in investment banking, executive, and financial leadership roles at publicly traded biotech companies, including Cardiff Oncology and Cidara Therapeutics. His compensation package includes an annual base salary of US$475,000, an annual target bonus of 40% of his base salary, and options over 200,000 American Depositary Shares, with specific severance provisions.

Kazia Therapeutics Limited filed a Form 6-K to furnish its investor presentation and a fact sheet, both dated April 27, 2026. These documents provide updated information to investors.